Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK.
Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry and compound management, all with access to in-house diversity and fragment libraries.
Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1.5 million compounds for our customers, in both liquid and solid formats.
Since 2013, the BioAscent team has been responsible for:
>150 biochemical, biophysical and cellular assays for drug discovery projects, across all key target classes including GPCRs, multiple enzyme classes (including covalent programmes), nuclear receptors, protein-protein, protein-DNA and protein-RNA interactions.
Multiple HTS and fragment screens using multiple libraries of up to 250k in size and triaged the outcomes of over 120 HTS campaigns.
>50 hit validation/characterisation projects.
>30 hit-to-lead campaigns, including successfully driving a project to candidate selection and out licensing to big pharma, and driving a second against an unprecedented target from initial hit finding to in vivo efficacy.
>100,000 screening plates to global customers and partners.
